PRESS RELEASE

Of interest to editors and journalists covering:
Medical/Hospitals, Medical Research, Biotech, Education, GA News


Health Discovery Corporation announces Agreement with Stanford University for Biomarker and Pathway
Discovery in Lymphatic Insufficiency.

SAVANNAH, GA - March 22, 2004 /Send2Press Newswire/  -- Health Discovery Corporation (OTC Bulletin Board:
HDVY) today announced the signing of an Agreement with Stanford University to use Health Discovery
Corporations proprietary and patent protected Fractal Genomics Modeling (FGM) techniques to identify new
patterns of biomarkers in lymphatic insufficiency and its response to therapeutic lymphangiogenesis.
According to the Agreement, ownership of Research Program Inventions conceived, discovered or reduced to
practice under the Research Program will be determined based on inventorship. As such, any invention
discovered using our analytical tools on this Stanford database will be jointly owned by Health Discovery
Corporation and Stanford.
 
Stephen D. Barnhill, M.D., Chairman and Chief Executive Officer of Health Discovery Corporation stated,
"It is an honor that Stanford will be working with our Company to utilize our unique approach to systems
biology to discover new patterns of biomarkers and pathways associated with lymphatic insufficiency."
 
According to the World Health Organization, lymphedema affects 250 million people worldwide. Others
estimate that one in every twenty-five will suffer from some form of lymphedema during their lifetime.
The M.D. Anderson Cancer Center in Houston, Texas reports that approximately 15% of all women with breast
cancer will develop lymphedema over the course of their lifetime and that lymphedema resulting from
prostate cancer is on the rise.

Health Discovery Corporation is a systems biology oriented biomarker and pathway discovery company, which
uses proprietary advanced mathematical platforms, such as Fractal Genomics Modeling (FGM) techniques, to
help identify and characterize diagnostic targets and therapeutic candidates. Focusing on disease vs.
normal, within complex genomic, proteomic and clinical data sets, Health Discovery Corporation was
established to provide pharmaceutical and diagnostic companies with a broad range of analytical and
decision support solutions to accelerate effective diagnostic and drug discovery. Founded in September
2003, the Company has offices in Texas, Georgia, and California. For more information contact Robert S.
Braswell IV of Health Discovery Corporation +1-866-953-9031.

This news release contains "forward-looking statements" within the meaning of Section 27a of the
Securities Acts of 1933 and Section 21E of the Securities Exchange Act of 1934. Although the Company
believes that the expectations reflected in such forward-looking statements are reasonable, it can give
no assurance that such expectations will prove correct.

More information: http://www.healthdiscoverycorp.com

	MEDIA CONTACT:
	Robert S. Braswell IV 
	of Health Discovery Corporation 
	+1-866-953-9031
	info@healthdiscoverycorp.com


( OTC Bulletin Board: HDVY )

 
# # #


[ source of news = Health Discovery Corporation ]
ref: http://www.send2press.com/2archive/2004/pr_04_0322-hdvy.txt
	 http://www.send2press.com/2archivePDF/pr_04_0322-hdvy.pdf
---------------------------------------------------------------------------
*IMPORTANT NOTE TO MEDIA:
	to reach the organization releasing this news, please contact:
	info@healthdiscoverycorp.com (media only)
	
	If used for publication, please send specimen copy.
---------------------------------------------------------------------------
S2PRN-R/4c/ GA / SAVANNAH, Georgia / Copr. (c) 2004 Send2Press.


This release was issued on behalf of the above organization,
who is solely responsible for accuracy of content,
by Send2Press(tm), a unit of Neotrope(R). http://www.Send2Press.com